Rheumatoid arthritis (n = 33) | Spondyloarthritis (n = 32) | Osteoarthritis (n = 18) | p-value | |
---|---|---|---|---|
Demographics | ||||
Female [n (%)] | 28 (85) | 8 (25) | 18 (100) | N/A |
Age [years; median (IQR)] | 57.0 (20–82) | 46.5 (18–74) | 68.0 (49–82) | N/A |
Time of disease < 2 years [n (%)] | 8 (24) | 12 (37) | 4 (22) | N/A |
Comorbidities | ||||
Smoking [n (%)] | 13 (40) | 5 (15) | 5 (28) | N/A |
Cardiovascular diseases [n (%)] | 21 (64) | 13 (40) | 12 (66) | N/A |
Diabetes mellitus [n (%)] | 2 (6) | 3 (9) | 3 (16) | N/A |
Dyslipidemia [n (%)] | 4 (12) | 3 (9) | 2 (11) | N/A |
Obesity [n (%)] | 4 (12) | 2 (6) | 5 (27) | N/A |
Fibromyalgia [n (%)] | 5 (15) | 1 (3) | 2 (11) | N/A |
Laboratory findings | ||||
CRP [mg/dL; median (IQR)] | 0.95 (0.4–3.1) | 1.2 (0.6–6.3) | 1.9 (0.5–3.4) | ns |
CRP > 1.0 [mg/dL; n (%)] | 16 (48) | 17 (53) | 10 (55) | ns |
ESR [mm/h; median (IQR)] | 23 (7–37) | 19 (8–40.7) | 20 (6–26) | ns |
ESR > 20 [mm/h; n (%)] | 18 (54.5) | 15 (46.8) | 7 (38.8) | ns |
Cell count [/mm3; median (IQR)] | 7675 (862–16950) | 8400 (2475–16,825) | 800 (250–1225) | < 0.01 |
Neutrophils [/mm3; median (IQR)] | 77 (62–85) | 72 (52–88) | 70 (43–76) | ns |
Medications | ||||
Methotrexate [n (%)] | 8 (25) | 2 (6) | – | ns |
Leflunomide [n (%)] | 8 (25) | 1 (3) | – | ns |
Sulfasalazine [n (%)] | 1 (3) | 5 (28) | – | ns |
TNF-blocker [n (%)] | 10 (30) | 16 (50) | – | ns |
Non TNF-blocker [n (%)] | 6 (18) | 1 (3) | – | ns |